Merck (MRK) Construction in Progress (2009 - 2025)
Merck (MRK) posted quarterly Construction in Progress of $9.2 billion for Q4 2025, up 14.8% YoY from $8.0 billion in Q4 2024, and up 14.8% sequentially from $8.0 billion in Q4 2024.
Merck (MRK) Construction in Progress (2009 - 2025) Analysis & Trends
Merck has disclosed Construction in Progress across 17 years of filings, most recently posting $9.2 billion for Q4 2025.
- In Q4 2025, Construction in Progress rose 14.8% year-over-year to $9.2 billion; the TTM figure through Dec 2025 stood at $9.2 billion (up 14.8% YoY), while the FY2025 annual figure was $9.2 billion, up 14.8% from the prior year.
- Construction in Progress grew to $9.2 billion in Q4 2025, from $8.0 billion in the prior quarter.
- Over the last five years, Construction in Progress for MRK reached as high as $9.2 billion in Q4 2022 and fell as low as $8.0 billion in Q4 2024.
- The 5-year median for Construction in Progress is $8.3 billion (2021), against an average of $8.6 billion.
- Annual changes were most pronounced in 2021 — Construction in Progress rose 19.3% — and 2023, when it retreated 10.06%.
- A 5-year view of Construction in Progress shows it stood at $8.3 billion in 2021, then increased by 10.5% to $9.2 billion in 2022, then retreated by 10.06% to $8.3 billion in 2023, then retreated by 3.36% to $8.0 billion in 2024, then increased by 14.8% to $9.2 billion in 2025.
- According to Business Quant data, Construction in Progress over the past three periods registered $9.2 billion, $8.0 billion, and $8.3 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.17 Bn |
| Dec 31, 2024 | 7.98 Bn |
| Dec 31, 2023 | 8.26 Bn |
| Dec 31, 2022 | 9.19 Bn |
| Dec 31, 2021 | 8.31 Bn |
| Dec 31, 2020 | 6.97 Bn |
| Dec 31, 2019 | 5.01 Bn |
| Dec 31, 2018 | 3.36 Bn |
| Dec 31, 2017 | 2.30 Bn |
| Dec 31, 2016 | 1.87 Bn |
| Dec 31, 2015 | 1.53 Bn |
| Dec 31, 2014 | 1.45 Bn |
| Dec 31, 2013 | 1.81 Bn |
| Dec 31, 2012 | 2.44 Bn |
| Dec 31, 2011 | 2.20 Bn |
| Dec 31, 2010 | 2.07 Bn |
| Dec 31, 2009 | 1.82 Bn |